Form 4: AbbVie Director Jennifer L. Davis Reports Stock Unit Acquisition
Statement of Changes in Beneficial Ownership
AbbVie Inc. director Jennifer L. Davis acquired 1,118 restricted stock units under the company's incentive program.
Summary
- Jennifer L. Davis, a Director at AbbVie Inc., acquired 1,118 restricted stock units (RSUs) on May 8, 2026.
- These RSUs were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program.
- The RSUs will be settled on a one-to-one basis in shares of AbbVie common stock.
- Settlement will occur upon the director's separation from service, death, or a change in control.
- Following this transaction, Ms. Davis beneficially owns 3,643 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation award and not a discretionary purchase or sale of stock by an insider.
Positives
- Director acquisition of company stock can signal confidence in the company's future prospects.
- The award of restricted stock units aligns management and director interests with shareholders.
Risks
- The value of the acquired RSUs is subject to market fluctuations in AbbVie's stock price.
- Vesting and settlement are contingent upon specific events (separation, death, change in control), introducing uncertainty regarding the timing of actual share receipt.
Future Outlook
The acquired restricted stock units are subject to settlement upon the occurrence of specific future events, including separation from service, death, or a change in control, at which point they will be converted into AbbVie common stock.
Industry Context
StockSavvy.ai notes that insider transactions, such as this acquisition of restricted stock units by a director, are common within the pharmaceutical and biotechnology sectors as a method of executive and director compensation and incentive alignment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Incentive Stock Program | Award of restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. | 05/08/2026 | Reinforces alignment of director interests with long-term shareholder value through equity-based compensation. |
Stakeholder Impact
- Shareholders: The acquisition of RSUs by a director can be viewed positively as it aligns director incentives with shareholder interests.
- Employees: The filing is part of standard corporate reporting and does not directly impact employees, though it reflects the company's compensation practices.
Next Steps
- Settlement of restricted stock units upon the director's separation from service, death, or a change in control.
Key Dates
| Date | Description |
|---|---|
| 05/08/2026 | Transaction Date for acquisition of restricted stock units. |
| 05/12/2026 | Date of signature for the filing. |
Keywords
AbbVie Inc., ABBV, Form 4, Insider Trading, Restricted Stock Units, Director Compensation, Securities Exchange Act, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.